29 Mar 2016 07:00
Cyprotex PLC
("Cyprotex" or "the Company")
Notification to shareholders under changes to UK reporting framework
Cyprotex PLC gives notice it has notified Shareholders that following the publication of FRS 100 'Application of Financial Reporting Requirements' by the Financial Reporting Council the Company is required to change the accounting framework used in preparing entity financial statements ("Parent Company accounts"). Previously the Parent Company accounts of the Company had been prepared under UK GAAP. For the year ended 31 December 2015 the Company intends to adopt FRS 101 'Reduced Disclosure Framework'. The Company's consolidated accounts will continue to be prepared under International Financial Reporting Standards and will be unaffected by this adoption.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | ir@cyprotex.com www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jen Boorer
| shaun.dobson@n1singer.com jennifer.boorer@n1singer.com www.n1singer.com |
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1300 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.